Gerasimos Krassas, Nikolaos Pontikides, Argyrios Dumas, Jan Frystyk, Jian-WenChen, Allan Flyvbjerg
The aim of this study was to investigate the effect of long-term somatostatin analogue (SM-a) treatment on serum levels of free (F) and total (T) insulin-like growth factor (IGF)-I, -II and IGF binding protein (IGFBP) – 1, -2 and -3 in euthyroid patients with active thyroid ophthalmopathy. For this purpose, we measured the above-mentioned parameters …
Roberta Giordano, Lorenza Bonelli, Elisa Marinazzo, Ezio Ghigo, Emanuela Arvat
This paper will focus on the rationale of using Growth Hormone (GH) as an anti-ageing therapy in the healthy elderly with age-related decline in the activity of the GH/IGF-I axis, the so called “somatopause”. Although the age-related decline in the activity of the GH/IGF-I axis is considered to contribute to age-related changes …
Bessie E. Spiliotis, Theodore K. Alexandrides, Christoforos Karystianos, Pavlos Vassilakos, Zvi Zadik, Nikoleta M. Nikolakopoulou, George Nikiforidis, Nicholas G Beratis
OBJECTIVE: The aim of the study was to evaluate the IGF-I generation test (IGF-I gen) as a possible indirect test of Growth Hormone (GH) secretory status. METHODS: Sixty-five GH deficient (GHD 1 and 2) and 86 control children were studied …
Mara Boschetti, Massimo Casu, Sara Moretti, Claudia Teti, Valeria Albanese, Manuela Albertelli, Giovanni Murialdo, Francesco Minuto, Diego Ferone
OBJECTIVE: This prospective study aimed to evaluate the impact of growth hormone deficiency (GHD) on cardiac autonomic tone and on cardiovascular risk and the changes after 12 months of GH replacement therapy (GHRT). GHD is associated with increased cardiovascular morbidity and mortality …